Logo

Enveric Biosciences Collaborates with Aries Science & Technology to Develop its Dermatitis Topical Product

Share this
Enveric Biosciences

Enveric Biosciences Collaborates with Aries Science & Technology to Develop its Dermatitis Topical Product

Shots:

  • Enveric Biosciences and Aries Science & Technology have entered into a licensing agreement to develop the former’s radiation dermatitis topical product
  • As per the agreement, Aries will pay a total of ~$61M milestones plus additional 2.5% to 10% sales-based tiered royalties, on meeting all the conditions. Agreement will be executed through Akos Biosciences (subsidiary of Enveric)
  • This product aims to relieve cancer patients from the painful side effects of radiation therapy. It is protected by an allowed US patent & a pending PCT application

Ref: Enveric Biosciences  | Image: Enveric Biosciences 

Related News: LEO Pharma’s Adbry (tralokinumab-ldrm) Autoinjector Receives the US FDA’s Approval to Treat Moderate-to-Severe Atopic Dermatitis (AD)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions